How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion
Nephrol Dial Transplant
.
2020 Jun 1;35(6):899-904.
doi: 10.1093/ndt/gfaa130.
Authors
Umberto Maggiore
1
,
Daniel Abramowicz
2
,
Marta Crespo
3
,
Christophe Mariat
4
,
Geir Mjoen
5
,
Licia Peruzzi
6
,
Mehmet Sükrü Sever
7
,
Gabriel C Oniscu
8
,
Luuk Hilbrands
9
,
Bruno Watschinger
10
Affiliations
1
Dipartimento di Medicina e Chrurgia, Università d Parma, UO Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
2
Department of Nephrology, Antwerp University Hospital, Antwerp University, Antwerp, Belgium.
3
Department of Nephrology, Hospital del Mar Barcelona, Barcelona, Spain.
4
Department of Nephrology, Dialysis, and Renal Transplantation, University North Hospital, Saint Etienne, France.
5
Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway.
6
Pediatric Nephrology Unit, Regina Margherita Children's Hospital, Turin, Italy.
7
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
8
Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.
9
Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
10
Department of Nephrology, Medical University of Vienna, Vienna, Austria.
PMID:
32441741
PMCID:
PMC7313836
DOI:
10.1093/ndt/gfaa130
No abstract available
Publication types
Comment
MeSH terms
Betacoronavirus
COVID-19
Coronavirus Infections
Edetic Acid
Humans
Immunosuppression Therapy
Kidney Transplantation*
Pandemics
Pneumonia, Viral
SARS-CoV-2
Transplant Recipients
Substances
Edetic Acid